The National traditional Chinese patent medicines and simple preparations Joint Procurement Office recently issued a notice, specifying that the national traditional Chinese patent medicines and simple preparations centralized procurement with quantity will be launched in the near future. This round of centralized procurement includes 42 traditional Chinese patent medicines and simple preparations. This round of national traditional Chinese patent medicines and simple preparations joint procurement is guided by the National Health Insurance Bureau, and the Hubei Provincial Health Insurance Bureau undertakes the daily work of the joint procurement office and is responsible for the specific implementation. Thirty two alliance regions, including Hubei Province and Beijing City, have appointed representatives to form the National traditional Chinese patent medicines and simple preparations Joint Procurement Office. Relevant medical institutions in the alliance regions will carry out centralized procurement of traditional Chinese patent medicines and simple preparations and related drugs in quantity. This round of centralized bulk procurement includes 16 procurement groups, including Compound Cantharidin, Compound Xueshuantong, and Guanxinning, with a total of 42 drug types. The administration routes include oral and injection. All public medical institutions (including military medical institutions) in the alliance region are encouraged to participate in centralized procurement, and designated social medical institutions and designated pharmacies under medical insurance are encouraged to participate in accordance with relevant regulations in the alliance region where they are located. The centralized procurement cycle with volume is 2 years, which can be extended depending on the situation. If the procurement cycle needs to be extended, the Joint Procurement Office will make a separate announcement before the end of the procurement cycle. During the procurement cycle, products that have not been selected shall be included in the monitoring and management of the alliance region. Medical institutions shall not purchase products that have not been selected more than 10% of the actual procurement volume of the same procurement group. (Outlook Society)